Genprex Stock Price, News & Analysis (NASDAQ:GNPX) $0.23 0.00 (0.00%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.23▼$0.2550-Day Range$0.20▼$0.3752-Week Range$0.19▼$1.94Volume309,720 shsAverage Volume181,848 shsMarket Capitalization$13.73 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Genprex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,198.7% Upside$3.00 Price TargetShort InterestHealthy2.25% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector226th out of 932 stocksPharmaceutical Preparations Industry81st out of 431 stocks 3.5 Analyst's Opinion Consensus RatingGenprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Genprex has a forecasted upside of 1,198.7% from its current price of $0.23.Amount of Analyst CoverageGenprex has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.25% of the outstanding shares of Genprex have been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Genprex has recently decreased by 18.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGenprex has received a 75.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Genprex is -0.78. Previous Next 0.6 News and Social Media Coverage Search Interest3 people have searched for GNPX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Genprex to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by Insiders11.54% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.05% of the stock of Genprex is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Genprex are expected to grow in the coming year, from ($0.49) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genprex is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genprex is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenprex has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genprex Stock (NASDAQ:GNPX)Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Read More GNPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNPX Stock News HeadlinesNovember 23, 2023 | finance.yahoo.comGenprex Granted Orphan Drug Designation in Small Cell Lung CancerNovember 16, 2023 | nz.finance.yahoo.comGenprex, Inc. (GNPX) stock price, news, quote & history – Yahoo FinanceDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | finance.yahoo.comGenprex to Present at BIO-Europe 2023November 1, 2023 | finance.yahoo.comGenprex to Present at BIO-Europe 2023 ConferenceOctober 20, 2023 | finance.yahoo.comGenprex Schedules, Hosts Virtual Key Opinion Leader EventOctober 20, 2023 | finance.yahoo.comGenprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"October 6, 2023 | finance.yahoo.comGenprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC ConferenceDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 4, 2023 | finance.yahoo.comGenprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 21, 2023 | finance.yahoo.comGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLCSeptember 20, 2023 | finanznachrichten.deNetworkNewsWire: Pathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationSeptember 8, 2023 | finance.yahoo.comGenprex to Present at Upcoming H.C. Wainwright ConferenceSeptember 4, 2023 | finance.yahoo.comGENPREX (GNPX) Upgraded to Buy: Here's What You Should KnowSeptember 2, 2023 | finance.yahoo.comGenprex Secures Patent Protection in 'Some of the Most Important Markets in the World'August 24, 2023 | finance.yahoo.comGenprex Appoints Regulatory Expert as It Drives Clinical Programs ForwardAugust 22, 2023 | finance.yahoo.comGenprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory AffairsAugust 13, 2023 | finance.yahoo.comGenprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLCAugust 5, 2023 | msn.comGenprex (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy CombinationAugust 5, 2023 | msn.comGenprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct OfferingAugust 5, 2023 | msn.comGenprex (NASDAQ: GNPX) Enters Exclusive License Agreement with University of PittsburghJuly 28, 2023 | finance.yahoo.comGenprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in ChinaJuly 25, 2023 | finance.yahoo.comGenprex Inc. Closes on $7.5M Registered Direct OfferingJuly 21, 2023 | finance.yahoo.comGenprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 21, 2023 | finance.yahoo.comGenprex Inc. Announces $7.5M Registered Direct OfferingJuly 20, 2023 | finance.yahoo.comGenprex Enters Exclusive License Agreement with University of PittsburghJuly 19, 2023 | msn.comGenprex prices stock and warrants offering to raise $7.5M; shares fallSee More Headlines Receive GNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNPX CUSIPN/A CIK1595248 Webwww.genprex.com Phone(877) 774-4679FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,198.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,740,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-194.71% Return on Assets-156.61% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.50Miscellaneous Outstanding Shares59,440,000Free Float52,576,000Market Cap$13.73 million OptionableNot Optionable Beta-0.10 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. John Rodney Varner (Age 66)Co-Founder, Chairman, President & CEO Comp: $886.97kMr. Ryan M. Confer M.S. (Age 41)Chief Financial Officer Comp: $606.57kMs. Catherine M. Vaczy Esq. (Age 62)Executive VP, General Counsel, Corporate Secretary & Chief Strategy Officer Comp: $704.93kMr. David M. SchlossSenior Vice President of Human ResourcesMr. Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property & LicensingDr. Mark S. Berger M.D. (Age 68)Chief Medical Officer Dr. Suzanne Thornton-JonesSenior Vice President of Regulatory Affairs & QualityDr. Jack A. Roth F.A.C.S.M.D., Chairman of Scientific & Medical Advisory BoardMore ExecutivesKey CompetitorsAcelRx PharmaceuticalsNASDAQ:ACRXLipocineNASDAQ:LPCNOnconova TherapeuticsNASDAQ:ONTXVirios TherapeuticsNASDAQ:VIRIHepion PharmaceuticalsNASDAQ:HEPAView All CompetitorsInsiders & InstitutionsAMH Equity LtdBought 813,135 shares on 11/6/2023Ownership: 1.369%Catherine M VaczyBought 20,000 shares on 4/21/2023Total: $21,400.00 ($1.07/share)John Rodney VarnerBought 19,000 shares on 4/21/2023Total: $19,950.00 ($1.05/share)View All Insider TransactionsView All Institutional Transactions GNPX Stock Analysis - Frequently Asked Questions Should I buy or sell Genprex stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNPX shares. View GNPX analyst ratings or view top-rated stocks. What is Genprex's stock price target for 2024? 1 brokerages have issued 12-month price targets for Genprex's stock. Their GNPX share price targets range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,198.7% from the stock's current price. View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts. How have GNPX shares performed in 2023? Genprex's stock was trading at $1.45 at the start of the year. Since then, GNPX stock has decreased by 84.1% and is now trading at $0.2310. View the best growth stocks for 2023 here. Are investors shorting Genprex? Genprex saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,340,000 shares, a drop of 18.3% from the October 31st total of 1,640,000 shares. Based on an average daily volume of 298,100 shares, the short-interest ratio is currently 4.5 days. View Genprex's Short Interest. When is Genprex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our GNPX earnings forecast. How were Genprex's earnings last quarter? Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), Advanced Micro Devices (AMD). Who are Genprex's major shareholders? Genprex's stock is owned by a number of institutional and retail investors. Top institutional investors include AMH Equity Ltd (1.37%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine M Vaczy and John Rodney Varner. View institutional ownership trends. How do I buy shares of Genprex? Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GNPX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.